Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I agree that 5/10 survival from the Montefiore coh

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155130
(Total Views: 688)
Posted On: 05/23/2020 6:12:46 PM
Posted By: Rex Eupseiphos
Re: TechGuru #35168
I agree that 5/10 survival from the Montefiore cohort is seems encouraging, but t-tests and binomial tests only make sense if you have good samples to work with. We really don't (yet).

I've been doing the same sorts of calculations in my head but have been also thinking about how reliable/unreliable they are given the garbage data that we have to work with. Yes, if we know a priori that p(mortality) = 0.88 for untreated patients like those in the Montefiore cohort, then I suppose your analysis makes some sense.

But it is completely unclear how the sample for that estimate of p_hat = 88% (not p) that you cite relates to the Montefiore cohort or the S Cal. cohort, and if it is even a little different, your p-values will swing wildly. Is the binomial p really 88%? Probably not. Maybe not even close. [https://www.npr.org/sections/health-shots/2020/05/15/856768020/new-evidence-suggests-covid-19-patients-on-ventilators-usually-survive --- docs estimating 20-50% mortality in Michigan]. The critical question is not so much what it is for some generic population, but what it is for the sample of patients in the experiment. We really have no idea.

I expect the p-values we see from actual, quality data will be somewhere between 0.001 and 0.4. I have seen some evidence to suggest it might be closer to 0.001 than 0.4, namely, the IL-6 levels drop pretty quickly after leronlimab is administered. A priori, this is a good sign because IL-6 is a primary cause of the killer inflammation. Also, clinical results with the IL-6 blocker, tocilizumab, have shown promise in France and China. Maybe leronlimab has additional benefits too, as suggested by Dr Patterson, but we still don't know.

In my opinion, it's crazy that a drug with a good safety profile and tantalizing anecdotal stories about effectiveness cannot be tried---except under extraordinary Big Brother oversight---even if the patient and his or her doctor wish to.

**************
P.S. I doubt very much that the FDA will be using a fixed and known binomial p in any analyses of the trial data!


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us